RxDoctor Payments Data

Kathy Santon, APRN

Psychiatric/Mental Health · Avon, INNPI 1306897913

Payments from drug & device makers

$2,325in general payments, 2019–2025

Across 138 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$503
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$371
  • Sunovion Pharmaceuticals Inc.$245
  • Eisai Inc.$172
  • Supernus Pharmaceuticals, Inc.$165
  • Corium, LLC$138
  • plus $731 from 12 others

What the payments were for

  • Food & beverage$2,27898%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,325 in reported general payments places this provider in the 75th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$16,874
Medicare patients
43
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole16$29,321
VraylarCariprazine Hcl16$26,623
Lurasidone Hcl23$6,620
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine66$2,404
Bupropion XlBupropion Hcl94$2,222
Aripiprazole30$1,887
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$1,650
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$1,622
Duloxetine Hcl62$1,217
Gabapentin57$1,015
Oxcarbazepine17$1,015
Hydroxyzine Hcl35$920
Lamotrigine62$806
Methylphenidate Hcl13$779
Quetiapine Fumarate43$732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$80$29,32116 claims
AbbVieVraylar$503$26,62316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Avon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →